Table 2.

Results of a multivariate regression analysis of tolvaptan treatment effect on change in eGFR to month 36 in TEMPO 3:4 with inclusion of change from baseline to week 3 in urine osmolality as a covariate

Parameter	Estimate	95% CI	P Value
Intercept, %	−12.91	−18.94 to −6.88	<0.00001
ΔUosm3, mOsm/kg	−0.01	−0.02 to −0.01	<0.00001
Age, yr	−0.169	−0.303 to −0.034	0.014
Sex (1, male; 2, female)	2.839	0.972 to 4.705	0.0029
Model with treatment and the above predictors (0, placebo; 1, tolvaptan)
Treatment, %	1.160	−1.093 to 3.414	0.31

CI, confidence interval; ΔUosm3, change from baseline to week 3 in urine osmolality.